Cargando…
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database
BACKGROUND AND OBJECTIVE: Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS...
Autores principales: | Ziyadeh, Najat J., Geldhof, Anja, Noël, Wim, Otero-Lobato, Marijo, Esslinger, Suzan, Chakravarty, Soumya D., Wang, Yiting, Seeger, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595963/ https://www.ncbi.nlm.nih.gov/pubmed/32779120 http://dx.doi.org/10.1007/s40261-020-00959-7 |
Ejemplares similares
-
Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan
por: Felo, Lauren, et al.
Publicado: (2019) -
Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)—a company experience
por: Esslinger, Suzan, et al.
Publicado: (2022) -
A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data
por: Dore, David D, et al.
Publicado: (2014) -
Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021) -
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
por: Tesser, John, et al.
Publicado: (2022)